Pulse Biosciences (PLSE)
NASDAQ:PLSE
PLSE Stock Chart & Stats
$22.02
-$0.27(-1.46%)
At close: 4:00 PM EST
$22.02
-$0.27(-1.46%)
Day’s Range― - ―
52-Week Range$12.56 - $26.30
Previous CloseN/A
Volume31.18K
Average Volume (3M)189.63K
Market Cap
$1.46B
Enterprise Value$1.39B
Total Cash (Recent Filing)$80.73M
Total Debt (Recent Filing)$7.53M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
May 07, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding67,989,075
10 Day Avg. Volume222,519
30 Day Avg. Volume189,626
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue3.97K
Enterprise Value/Gross Profit-1.94K
Enterprise Value/Ebitda-19.03
Forecast
1Y Price Target
$30.00Price Target Upside36.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.33
Revenue Forecast (FY)$3.40M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyConsistently high procedural success and durable 12-month outcomes materially de-risk the core technology. Durable efficacy supports physician preference, facilitates payer conversations and hospital adoption, and increases the likelihood that pivotal trials will translate into sustainable clinical adoption over coming regulatory milestones.
Regulatory Pathway ProgressSecuring IDEs and defined pivotal enrollment plans establishes a clear route to market in both U.S. and EU jurisdictions. This reduces regulatory uncertainty, enables structured data collection for labeling and reimbursement, and positions the company to convert clinical momentum into near‑term regulatory milestones and eventual commercial clearance.
Growing IP EstateRapid expansion of granted and pending patents strengthens barriers to entry around nsPFA technology. A broader IP portfolio supports exclusivity, licensing leverage and competitive differentiation—important in med‑device markets with long development cycles and where IP deters fast follower risks.
Bears Say
Minimal RevenueThe company remains fundamentally pre‑commercial with negligible product revenue and widening losses. For a razor‑and‑blades model, lack of an installed base and absent recurring consumable revenue means commercialization economics are unproven and scale will require successful regulatory clearances plus sustained investment to reach positive gross margins.
Accelerating Cash BurnOperating cash outflows have increased materially year‑over‑year, stressing liquidity and forcing reliance on external financing. Sustained negative cash generation limits flexibility to scale commercial operations or expand trials without dilutive raises or partnerships, making execution on multi‑quarter regulatory and reimbursement plans contingent on new capital.
Commercial Execution RiskLoss of the head of commercial execution during transition from limited launch to broader market roll‑out raises implementation risk. Replacing senior commercial leadership or reorganizing amid pivotal trial and reimbursement work can slow system placements, dealer/partner development, and adoption ramp, extending the timeline to sustainable consumable revenue.
Pulse Biosciences News
PLSE FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $26.30 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $1.46B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is May 07, 2026 which is in 41 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on Feb 19, 2026. The company reported -$0.183 earnings per share for the quarter, beating the consensus estimate of -$0.265 by $0.082.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.27.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 67,989,075 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.183 in its last earnings report, beating expectations of -$0.265. Following the earnings report the stock price went down -14.593%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in PLSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (36.24% Upside)
$30.00 (36.24% Upside)
Blogger Sentiment
Bullish
PLSE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 11.6K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
-73.46%
Trailing 12-Months
Asset Growth
-28.30%
Trailing 12-Months
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
PLSE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong clinical and technology progress—IDE approvals, compelling early efficacy data with high 12‑month success rates, rapid procedure times, and substantial IP expansion—which materially de-risks key scientific and regulatory milestones. However, the financial picture remains early-stage: product revenue is still nominal, gross margin was effectively negligible in the quarter, operating losses persist, cash reserves declined substantially year-over-year, and broader commercialization hinges on additional regulatory clearances and reimbursement processes that may take multiple quarters. Overall, the narrative balances important clinical/strategic momentum against clear near-term financial and commercialization constraints.View all PLSE earnings summariesPLSE Stock 12 Month Forecast
Average Price Target
$30.00
▲(36.24% Upside)
Technical Analysis
Ownership Overview
73.34% Insiders
2.28% Mutual Funds
1.48% Other Institutional Investors
20.13% Public Companies and
Individual Investors